QPPV.COM KNOWLEDGE ASSESSMENT

Mirikizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Mirikizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which description best captures Mirikizumab's molecular and functional classification?

A humanised IgG4 monoclonal antibody that inhibits the IL-23 p19 subunit A small-molecule inhibitor that blocks tumour necrosis factor alpha A chimeric antibody that activates the IL-17 receptor A corticosteroid that broadly suppresses transcription of inflammatory genes

Question 2 of 10 What is the main purpose of preserving the benefit population in periodic benefit-risk evaluation?

To ensure that risks are interpreted against the patients and outcomes for whom treatment benefit is expected To avoid reviewing serious adverse events outside clinical trials To replace safety analysis with efficacy reporting To allow all indications to be treated as having identical background risk

Question 3 of 10 Which governance evidence would most convincingly demonstrate that an organisation's Mirikizumab follow-up process is effective?

A procedure exists and is approved by management Records show that required follow-up was sent, evaluated and incorporated into the case or aggregate assessment The product has no unresolved cases in the database All cases use the same follow-up questionnaire regardless of event type

Question 4 of 10 A product-quality investigation is opened after several administration-related complaints. Which information is most important for identifying a common product or process issue?

Presentation, batch, expiry, storage, preparation, administration system and associated cases Only the patient's preferred route of administration Only the clinical indication Only whether the event was coded as serious

Question 5 of 10 A patient develops a serious infection while receiving Mirikizumab with another immunomodulatory therapy. Which assessment is most appropriate?

Attribute the infection to Mirikizumab alone because it is the newest treatment Assess Mirikizumab, the concomitant therapy, baseline immune status, procedures, organism and disease context as potential contributors Exclude a treatment contribution because infections are common in inflammatory bowel disease Record the infection only as a class effect without documenting individual case evidence

Question 6 of 10 Which scenario best illustrates a failure to distinguish treatment interruption from complete dechallenge?

A patient stops Mirikizumab briefly, but the event continues while the drug's biological effect may persist A patient receives the documented dose and has no subsequent symptoms A patient has an event before the first exposure A patient switches from one product presentation to another with no clinical event

Question 7 of 10 How should rechallenge generally be treated in Mirikizumab case assessment?

As a routine test that should be performed whenever causality is uncertain As potentially informative evidence, while recognising that it may be clinically inappropriate As evidence that excludes all alternative causes As irrelevant because only the first exposure matters

Question 8 of 10 A periodic review pools induction and maintenance cases across different indications without documenting treatment phase. What is the principal concern?

The analysis may obscure differences in exposure, disease risk, treatment intent and event timing Pooling always makes the analysis more statistically valid Treatment phase is relevant only for efficacy, not safety Indication and phase can be reconstructed reliably from the preferred term

Question 9 of 10 Which follow-up package would be most useful for evaluating a suspected opportunistic infection?

Site, organism, cultures, imaging, antimicrobial treatment, immune status and outcome Only the date of the next Mirikizumab dose Only the reporter's statement that the event was serious Only the patient's treatment indication

Question 10 of 10 Which statement best describes the role of dechallenge in causality assessment?

Improvement after treatment interruption proves Mirikizumab caused the event Dechallenge may support a hypothesis but can be confounded by treatment of the event or persistence of biological effect Dechallenge is irrelevant for biological medicines A dechallenge is complete whenever the next scheduled dose is omitted

QPPV.com

Mirikizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings